Jason L Aldred

8PUBLICATIONS
55CO-AUTHORS
Clinical pharmacology and therapeuticsToxicology (incl. clinical toxicology)Biomedical instrumentationPharmaceutical delivery technologiesMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 04, 2025
Improvement in Motor Consistency and Stability with Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: Post Hoc Analysis of Two Phase 3 Clinical Trials.

Rajesh Pahwa, Jason Aldred, Michael J Soileau

|Jul 30, 2025
Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease.

Jason Aldred, Manon Bouchard, Juan Carlos Martínez-Castrillo

|Jun 06, 2025
Sustained Therapeutic Benefits Using Image-Guided Programming at Activation of Deep Brain Stimulation for Parkinson's Disease.

Jason L Aldred, Theresa Zesiewicz, Michael S Okun

|Oct 10, 2023
Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.

Jason Aldred, Eric Freire-Alvarez, Alexander V Amelin

|Aug 26, 2023
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.

Jason Aldred, Eric Freire-Alvarez, Alexander V Amelin

|Jun 08, 2022
Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease.

Danna Jennings, Sarah Huntwork-Rodriguez, Anastasia G Henry

Pageof 2

Frequent Collaborators

3 joint publications

Victor S C Fung

3 joint publications

Camille Carroll

3 joint publications

Thomas Kimber

3 joint publications

K Ray Chaudhuri